ESP Webinar about Molecular Testing on ctDNA in Patients with HR+, HER2- Advanced Breast Cancer
Clinical relevance and considerations for implementation5 February 2026 | 15:00 - 16:30 CET
Webinar Overview
The European Society of Pathology (ESP) with the collaboration of the ESP Breast Pathology working group, and the support from AstraZeneca is proud to organise this webinar.
The objective of this webinar is to discuss the benefits and drawbacks of liquid biopsy for breast cancer
As is the case with all ESP webinars, this series will be recorded and made available to ESP members via the ESP Educational Platform.
Supported by
Faculty
Speakers:
- Professor Peter Fasching, University Hospital Erlangen, Erlangen, Germany
- Professor Nicola Fusco, European Institute of Oncology (IEO), Milan, Italy
Moderators:
- Professor Xavier Matias Guiu, Hospital Universitari Arnau de Vilanova, Lleida, Spain. ESP President
- Professor Aleš Ryška, Charles University Medical Faculty, Hradec Králové, Czech Republic.
Webinar Programme
- Welcome and introduction
- Overview of liquid biopsy/ctDNA testing in the management of patients with cancer
- Acquired ESR1 mutations in the management of patients with HR+, HER2- ABC: clinical relevance and approaches to their identification
- Implementing ESR1 testing on ctDNA: practical and technological considerations
- Discussion and Q&A
Registration
The webinar is offered free of charge and will be conducted via ZOOM.
Please click on the below button to register.
Certificate of Attendance
- ESP members who participate in the live webinar will receive a personalised certificate of participation.